Summary We evaluated performance of FRAX in older men who participated in the Osteoporotic Fractures in Men (MrOS) study. Introduction FRAX has been extensively studied in women, but there are few studies of its performance in men. Methods FRAX estimates for 10-year hip fracture and major osteoporotic fracture (MOF; either hip, clinical spine, forearm, or shoulder) were calculated from data obtained from MrOS participants and compared to observed 10-year fracture cumulative incidence calculated using product limit estimate methods, accounting for competing mortality risk. Results Five thousand eight hundred ninety-one men were followed for an average of 8.4 years. Without bone mineral density (BMD) in the FRAX model, the mean 10-year predicted fracture probabilities for hip and MOF were 3.5 % and 8.9 %, respectively; addition of BMD to the calculations reduced these estimates to 2.3 % and 7.6 %. Using FRAX without BMD, predicted quintile probabilities closely estimated cumulative incidence of hip fracture (range of observed to predicted ratios 0.9-1.1). However, with BMD in the FRAX calculation, observed to predicted hip fracture probabilities were not close to unity and varied markedly across quintiles of predicted probability. For MOF, FRAX without BMD overestimated observed cumulative incidence (range of observed to predicted ratios 0.7-0.9) and addition of BMD did not improve this discrepancy (range of observed to predicted ratios 0.7-1.1). Addition of BMD to the calculation had mixed effects on the discriminatory performance of FRAX, depending on the analysis tool applied. Conclusion Among this cohort of community-dwelling older men, the FRAX risk calculator without BMD was well calibrated to hip fracture but less well to MOF.
Introduction
FRAX is the worldwide fracture risk assessment tool [1, 2] and has been incorporated into osteoporosis management and treatment guidelines in the US [3] and abroad [4] . The International Osteoporosis Foundation (IOF) has recently offered FRAX estimates in multipatient entry mode [5] ; this could allow data from electronic medical records or large patient cohorts and registries to be batch processed for research studies and population management programs.
Two published studies of FRAX's predictive performance in men are currently available [6, 7] . Yun et al. used area under the receiver operating curve (AUC) analyses to assess US FRAX performance for hip fracture among Medicare beneficiaries 65 years and older; the C-statistic of 0.67 was the same as that obtained in older women in the same cohort [6] , and the performance of FRAX (calculated without bone mineral density (BMD)) was significantly worse than fracture risk estimated from a simple model using only administrative claims data. Leslie et al. performed more extensive analyses to assess calibration of Canadian FRAX against observed hip and major osteoporotic fracture (MOF) probabilities among men and women in a Manitoba, Canada database [7] . Although limited by small numbers of fractures in men (43 hip and 163 MOF), they concluded there was "reasonable agreement between observed and predicted hip fracture rates"; the FRAX tool, with BMD included, minimally overestimated the observed hip fracture probability. In contrast, they reported that agreement between observed and predicted MOF was "more variable" with an overall 24 % underestimation. This group was also able to assess the possible contribution of BMD to the FRAX estimates. Compared to results obtained without BMD, addition of BMD to the calculation had minimal (<10 % reduction) effects on FRAX-estimated hip fracture and MOF probabilities but significantly increased the AUC.
Performance of an alternative fracture risk tool (FRC) in the Osteoporotic Fractures in Men (MrOS) study cohort was recently published [8] . Based on measures of calibration and discrimination, the tool showed promising results; further, addition of BMD to the FRC estimation minimally altered the risk estimates.
The MrOS cohort of older men has been closely followed for fracture up to 10 years, [9, 10] and thus provides an excellent opportunity to evaluate FRAX's calibration and discrimination. Our primary analysis goal was to determine how closely FRAX-predicted estimates would mirror observed fracture probabilities in the MrOS cohort. Our secondary analysis goal was to determine the ability of FRAX scores to discriminate individuals who would subsequently fracture from those remaining fracture free. In both analyses, we hypothesized that addition of BMD would enhance FRAX's predictive performance.
Methods

Participants
The MrOS study is a prospective cohort study designed to examine the extent to which fracture risk is related to various factors. Design and recruitment have been previously described. [9, 10] Bone and mineral density BMD (gram per square centimeter) of the total hip and hip subregions was measured using dual-energy x-ray absorptiometry (DXA) (QDR 4,500 W, Hologic, Inc., Waltham, MA, USA) [9] ; femoral neck BMD in grams per square centimeter was used as the FRAX input variable. T-scores and Z-scores for the femoral neck were calculated based on the race-specific means and standard deviations for men obtained from the National Health and Nutrition Examination Survey III (NHANES III) [11] .
Other risk factors All participants completed questionnaires, which included items about demographics and medical history including rheumatoid arthritis, fracture history, parental hip fracture history, smoking status, and alcohol consumption. Ethnicity was self-reported. The history of any fracture after age 50 was gathered by self-report. Prescription and nonprescription medications used within the preceding 30 days were identified, recorded by the clinics, and stored in an electronic medications inventory database (San Francisco Coordinating Center, San Francisco, CA, USA); each medication was matched to its ingredient(s) based on the Iowa Drug Information Service (IDIS) Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, IA, USA) [12] . Input values for secondary osteoporosis were set to null when passed to the risk calculator due to lack of clinical information on the conditions associated with bone loss; the FRAX calculation algorithm ignores this variable when BMD is included in the model. A comprehensive examination included measurements of body weight and height; BMI was calculated as weight in kilograms divided by the square of height in meters.
Bisphosphonate use occurring after the baseline visit was also gathered at the Interim visit (2.0±0.2 years from baseline), the Sleep visit (3.4±0.5 years from baseline), Visit 2 (4.6±0.4 years from baseline), Visit 3 (6.9±0.4 years from baseline), and Interim Visit 2 (8.9±0.4 years from baseline). Use was defined as any bisphosphonate reported to be taken within 30 days prior to a visit.
Incident fracture
After the baseline exam, surviving participants completed and returned a questionnaire about incident fractures every 4 months; response rates exceeded 99 %. Incident fractures were confirmed by centralized physician review of radiology reports or radiologist review of clinical x-rays. The fracture outcomes of interest in this analysis were hip fracture and fracture of either the hip, wrist, shoulder, or clinical spine (MOF), regardless of the degree of trauma.
Follow-up time for the fracture analyses was truncated to 10 years to correspond with the 10-year fracture risk estimates from FRAX. Thus, follow-up time ended at the time of the first fracture of that type, time of death, termination from MrOS, or after 10 years of follow-up. For those 418 (7.1 %) men who started use of a bisphosphonate after the baseline visit, the follow-up time was truncated to the midpoint between the last known visit when they were nonusers and the first visit bisphosphonate use was recorded.
Statistical analysis
Risk factors of participants were compared across 10-year fracture risk categories established by the National Osteoporosis Foundation (NOF) cost effectiveness analyses (3 % for hip fracture and 20 % for MOF) [13] using chi-square tests for categorical variables, t tests for normally distributed continuous variables, and Wilcoxon rank-sum tests for continuous variables with skewed distributions. Calibration (comparison of observed cumulative incidence to predicted probabilities) of the FRAX tool was evaluated using five risk subcategories. The Kaplan-Meier product limit method was used to calculate 10-year cumulative incidence probabilities of fracture in the presence of the competing risk of mortality, with observations censored at 10 years or end of follow-up or the start of bisphosphonate use (whichever came sooner). These observed cumulative incidences were determined for men in each quintile of 10-year fracture probability estimates determined from FRAX and ratios of observed to predicted probabilities were calculated within and across these quintiles.
Logistic regression models with fracture as the outcome and the corresponding FRAX 10-year fracture risk estimate as the predictor were performed. From these models, receiver operating characteristic (ROC) curves were created to compare sensitivity and specificity of the FRAX risk estimates, and the areas under the curves (AUC, C-statistic) ware calculated. The ROC curves for the fracture risk estimates with and without BMD used in the risk calculation were compared to examine if the addition of BMD to the risk calculator improved the AUC; a C-statistic value of 0.5 is no better than chance alone and 1.0 is perfect prediction.
Reclassification of risk after the addition of BMD to the risk calculator was also assessed using Net Reclassification Improvement (NRI) [14] [15] [16] . For these analyses, we used clinical cut points based on the NOF cost effective analyses [13] as well as a no-category approach [14] . Risk stratification tables were created to evaluate the incremental value of adding BMD to the risk prediction calculator [15, 16] . In the categorical NRI approach, the NRI sums the proportions of individuals who are appropriately (e.g., moving from a lower to a higher risk category for those who did go on to fracture) moved between risk categories and subtracts those moving inappropriately (e.g., moving from a higher to a lower risk category for those who did go on to fracture); these calculations are first performed separately by incident fracture status and then combined. The range of the NRI using the categorical approach is −100 % to 100 %, with positive values indicating a net reclassification in the appropriate direction and negative values indicating inappropriate reassignment; the higher the positive value, the better the reclassification. Using the no-category approach, we determined the proportions among those with incident fractures whose risk estimate was increased with addition of BMD and subtracted the proportion of those fracturing who moved inappropriately to lower risk estimates with BMD addition. Similar calculations were performed among those men who did not sustain an incident fracture. The overall NRI using the no-category approach is the sum of the fracturing and nonfracturing NRIs and could range from −200 % to +200 %.
A number of sensitivity analyses were performed, including removal of those men from the analyses who were missing data on any of the characteristics used by the risk calculator, removal of those both alive and fracture free but having less than the full 10 years of follow-up, and using all available follow-up information for those 418 men who began bisphosphonate therapy. All significance levels reported were two-sided and all analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) or Stata version 12.0 (StataCorp, College Station, TX, USA).
Results
Of the 5,891 men included in this analysis, 161 (2.7 %) had an incident hip fracture and 374 (6.4 %) had an incident MOF. The men were followed for an average of 8.4 ± 2.3 years. Of those 4,671 men with less than 10 years of follow-up, 337 had an incident MOF before end of followup, 1,471 died without having an incident MOF, and 2,863 men simply had less than full follow-up time. Among the latter group, 221 had terminated from MrOS and the remainder were still participating in the study with an average (±SD) follow-up time of 9.1±1.2 years, ranging from 7.3-9.99 years. As previously shown, the cohort was predominately white (89.6 %) with an average age at enrollment of 73.5±5.8 years and a femoral neck BMD Z-score +0.2 [8] .
Data was complete for all risk factors passed to the risk calculator for 4,291 (72.9 %) men [8] . The factors' most commonly missing data were information on parental history of hip fracture (23.9 %) and information on medications used for the definition of corticosteroid use and secondary osteoporosis (4.1 % missing). Other risk factors had missing data for nine or fewer men.
The mean (±SD) FRAX 10-year predicted fracture probabilities for hip and MOF without BMD in the model were 3.5 % (3.6) and 8.9 % (4.6), respectively. Addition of BMD to the calculation reduced these estimates to 2.3 % (3.1) and 7.6 % (4.3), respectively. Table 1 shows baseline characteristics of the cohort by NOF treatment cut point thresholds. In contrast to the 22 % of the cohort who met or surpassed the hip fracture threshold, only 2 % met or surpassed the MOF threshold. As expected, many of the fracture risk factors were statistically significantly different between those at or above versus those below these thresholds; these included age, BMI, prior fracture, parent with hip fracture, corticosteroid use, rheumatoid arthritis, and BMD. Table 2 compares fracture incidence rates per 1,000 patient years in the study cohort to published rates for men employed by US FRAX [17] . Of all hip fractures, 93 % occurred in men 75 years and older; of all MOFs, 86 % occurred in this age group. Among men in this older age group, the rate of hip fracture was approximately 35-38 % lower among men in MrOS compared to the National Inpatient Survey (NIS). The rates of MOF in MrOS were quite close to the calculated rates offered in the same publication.
Overall, the median predicted FRAX 10-year fracture probabilities (using BMD) were 1.4 % and 6.5 % for hip fracture and MOF, respectively, while observed median cumulative incidences were 3.0 % and 6.9 %. The tool's predictive accuracy is further shown in Fig. 1a and b, where relationships between observed cumulative incidences and predicted probabilities of fracture at 10 years are examined within each quintile of estimated risk. For hip fracture without BMD, the tool estimated risk fairly accurately (the average of observed to predicted ratios across the five quintiles was 1.0; range of these five ratios was 0.9-1.1), whereas this same calculation with BMD yielded an average ratio of 1.3 due to the tool's underestimation in four of the five risk quintiles (range of these five ratios was 0.4-2.0). In contrast, for MOF, FRAX generally overestimated risk yielding an average of observed to predicted ratios across five quintiles of 0.8 without BMD and 0.9 with BMD in the calculation (ranges of these five ratios were 0.7-0.9 and 0.7-1.1, for BMD excluded and included, respectively). We next examined the discrimination performance of FRAX. Figure 2a Superimposed on the ROC curves are the points where the NOF treatment thresholds fall (3 % for hip fracture and 20 % for MOF); without including BMD in the calculations, the NOF cut points correspond to sensitivities/1−specificities of 0.68/0.39 for hip fracture and 0.06/0.03 for MOF, respectively.
Using NOF cut points to calculate the contribution of BMD to FRAX by the Net Reclassification Index (NRI), we found appropriate movement (from higher to lower NOF risk category) among those who did not go on to have a hip fracture (NRI018.3 %, P<.001). However, adding BMD to the model resulted in a tendency for inappropriate movement (from high to low risk category) for those who subsequently had an incident hip fracture (NRI0−6.9 %, P0.09). The overall NRI for hip fracture was thus 11.4 % (P0.006) ( Table 3 ). In contrast, for MOF, adding BMD resulted in a statistically significant but minor appropriate reclassification of those without an incident fracture (NRI00.9 %, P<.001) and no improvement in overall NRI or NRI specific to those who fractured (Table 4) .
Using the no-category NRI approach, BMD addition significantly (P0.03; P<.001) reduced the NRI among those Fig. 1 a Cumulative (%) incidence of hip fracture (accounting for competing risk of mortality) versus predicted (%) FRAX probability of hip fracture, with and without BMD, by quintiles of FRAX 10-year fracture probability estimates. b Cumulative (%) incidence of major osteoporotic fracture (MOF) (accounting for competing risk of mortality) versus predicted (%) FRAX probability of MOF, with and without BMD, by quintiles of FRAX 10-year fracture probability estimates going on to suffer either an incident hip fracture or a MOF (Table 5 ). This was especially noted among older men with subsequent hip fracture; among those 75 years and older, addition of BMD to the FRAX calculation resulted in a negative NRI (−33.6 %), whereas among those less than 75 years, BMD addition produced a positive NRI (27.3 %).
In contrast, among those subsequently found to be free of incident fracture, addition of BMD significantly (P<.001;
P<.001) increased the NRI by appropriately lowering risk levels for both hip fracture and MOF. Thus, BMD addition significantly (P<.001; P<.001) increased the overall NRI (45.6 % and 24.3 % for hip fracture and MOF, respectively) but only through appropriate movement of risk downward for those free of incident fracture. Our findings were not altered in the two sensitivity analyses removing men with any missing risk factor data and allowing for full follow-up of those men who began bisphosphonate use. After removing those 2,863 men who had less than 10 years of follow up but had neither died nor suffered an incident fracture, NRI scores and area under the ROC curves were also similar to the primary analyses; as expected, removing from analyses a large number of men who were fracture free artificially increased the calculated proportions with fracture.
Discussion
We found that the FRAX risk calculator without BMD calibrates well to hip fractures but less well to MOFs observed among older men in the MrOS cohort. However, addition of BMD to the FRAX calculation lowers risk estimates (by 34 % for hip and by 15 % for MOF) and has inconsistent effects on the tool's fracture prediction performance. On the one hand, BMD inclusion increases the AUC C-statistic and improves discrimination among those who do not subsequently fracture, while, on the other hand, it both negatively affects calibration (observed versus predicted probabilities) and assignment of appropriate higher risk to those who ultimately go on to fracture. Assessing the performance of a risk tool involves several assumptions. Tests of calibration involve grouping individuals into risk categories (e.g., quintiles or clinical value categories) and observing relationships between the median of each predicted risk category and the observed cumulative incidence of fracture after accounting for competing mortality within that category. Conversely, tests of discrimination examine individuals and the correctness of risk categorization based on subsequent fracture versus no fracture status; this approach can use cut points for categorization, if available. If not, no-category analyses are appropriate. Finally, area under the ROC curve examines the relationships between test sensitivity and specificity across all levels of risk.
Statistical methods used to evaluate risk tools have become more sophisticated in recent years and we have learned of the limitations of previous methods [14] [15] [16] 18] . Whereas AUC was the most widely used method to assess the performance of risk tools, its limitations have been recognized [18] . Reclassification analyses have been suggested as the preferred method to assess the impact of added input variables on risk model performance. Additionally, limitations of comparative fracture assessment studies have been summarized [19] . In designing our study, we were cognizant of these issues and aware of the newer analytic approaches. First, we avoided making comparisons across studies or tools-focusing on one risk tool and one cohort. Second, we did not attempt to create new, simpler tools for comparison, but instead examined FRAX performance with and without inclusion of its BMD parameter. Third, we calculated cohort fracture probabilities over many years rather than extrapolating from short-term incidence rates; having a large cohort with most men followed up to 10 years provided hundreds of fractures and robustness to our analyses. Recognizing the insensitivity of area under ROC curves [18] to the inclusion of any additional risk factor, we performed NRI studies to assess BMD's contribution to risk levels of individuals. Finally, when calculating fracture probabilities, we adjusted for the known relationship between FRAX score and death hazard [19] .
Our study finding confirms other reports, both in men [20] and women [21, 22] , that adding BMD to FRAX yields lower predicted fracture risk estimates. How does this contribute to the tool's performance? We [8] and others [23] have found that addition of BMD increases AUC. Yet in the current study, we found that calibration and other measures of discrimination (e.g., NRI) appeared no better (or even worse) when BMD was included in the calculation. By reducing risk estimates, BMD reduced the likelihood of an inappropriately high risk estimate in the large proportion of men who did not fracture; however, this also reduced its ability to identify those going on to fracture. The net effect of lower risk estimates was "improvement" because the proportion not fracturing was many times greater than those fracturing-indeed >90 % of the MrOS cohort did not sustain an outcome fracture during follow-up. Further, the better discrimination of hip fracture over MOF that we observed could be driven by hip fracture incidence being less than half that of major fractures. Thus, correct reassignment performance in this cohort with BMD appears to be a trade-off between inappropriate lower risk estimates among the few destined to fracture offset by appropriate lower risk estimates among the many not going on to fracture. Our study has several strengths. The baseline input data are fairly complete on a large number (nearly 4,300) of men. The follow-up for incident fracture is 99 % complete and self-reported fractures were validated by review of radiograph reports; fractures were recorded up to 10 years and the majority of subjects had length of follow-up close to the 10-year value used by in the risk calculation, thus obviating the need to extrapolate. We performed several sensitivity analyses, confirming the robustness of our results despite missing data or truncated follow-up.
Limitations include drug exposure information based only on the 30 days prior to baseline and no information on dosage of glucocorticoids. We did not exclude fractures on the basis of degree of trauma; there are several reasons for this. First, determining degree of trauma is challenging. Second, FRAX 10-year estimates are for fractures of any degree of trauma, thus making comparisons of observed and predicted fracture events more valid. Finally, Mackey et al. [24] showed that low and high trauma fractures observed in both older men (MrOS) and older women (Study of Osteoporotic Fractures) were similarly associated with low BMD.
MrOS is an epidemiological observational study and a healthy volunteer bias could be present. The fact that the group's mean BMD Z-score was +0.2 suggests that these men are at substantially less risk for fracture (assuming RR 2.0 per SD BMD, the +0.2 Z-score translates into 40 % lower fracture risk). Our finding that hip fracture incidences among the MrOS cohort are somewhat lower than those obtained from the US NIS (rates used by FRAX) supports this contention. The MOF rates used by FRAX are the product of cobbling together NIS hip fracture rates with wrist and humerus fracture rates from Rochester, MN, USA, to which estimates of clinical spine fracture rates are added based on ratios of clinical spine to hip fracture incidence in Swedish data, and finally, adjusting the MOF rate downward to account for overlap of multiple fractures in the same individuals [17] . Despite the multiple assumptions and opportunities for miscalculation in these data, the MOF incidences among the older men in the MrOS cohort are remarkably close to the base fracture rates used by FRAX. We excluded 1.7 % of the cohort at baseline because they reported taking bisphosphonates, thus making the remaining cohort less prone to fracture than the original cohort, but those remaining also had lower fracture risk scores as a result of the winnowing.
We believe that FRAX performance or the performance of other fracture risk prediction tools are best evaluated using several measures of both calibration and discrimination, as well as newer measures of risk reclassification. Furthermore, these evaluations should be performed in a population similar to the target population in which the tool will be applied. The results of our study, taken in the context of other work in this area, indicate that age and sex greatly affect a fracture risk calculator's performance. This effect could be explained by marked differences in observed fracture incidence rates in various populations.
In conclusion, among community-dwelling, ambulatory, older men in the MrOS cohort, the FRAX calculator without BMD calibrates reasonably well with both hip and MOFs observed. Also, without BMD, the tool's ability to discriminate between men who will and will not experience these fracture outcomes appears adequate only for population management, i.e., categorizing groups by risk level. However, addition of BMD to the tool's calculations shows differential effects on fracture risk estimates and does little to improve its predictive performance. These issues require explanation and call for care in the way we evaluate any fracture risk tool's performance.
